Diagnosis and Treatment of Leishmania Infections

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Jun 23, 2006

Keywords

ClinConnect Summary

**Summary of the Clinical Trial on Leishmania Infections**

This clinical trial is investigating leishmaniasis, which is an infection caused by parasites that can affect the skin and other parts of the body. The study aims to learn more about how these infections develop and respond to various treatments, with the hope of improving diagnostic tests and treatments. If you or a family member is between the ages of 3 and 100 and has been diagnosed with leishmaniasis or has symptoms suggesting the infection, you may be eligible to participate.

Participants will undergo some routine tests, including blood work and a biopsy, which is a procedure to collect a small tissue sample to confirm the infection. Depending on the type of leishmaniasis, treatment could involve medications given by infusion (like Pentostam or amphotericin B) or taken by mouth (like itraconazole). Participants might also have follow-up visits to monitor their progress. This trial not only seeks to enhance our understanding of the disease but also offers a chance to contribute to future research that could benefit others facing similar health challenges.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Individuals aged 3 to 100 years.
• * Diagnosis of leishmaniasis:
• • A: Biopsy proven
• • OR
• B: Likely diagnosis of leishmaniasis based on :
• • Epidemiologic exposure, clinical manifestations, and time course
• • -Willingness to allow samples to be stored for future research.
• EXCLUSION CRITERIA:
• • Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.